London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


V4b toric and V4c toric implantable collamer lens for myopic astigmatism: 6 month follow-up

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Posterior chamber Phakic IOLS for correction of Myopia

Session Date/Time: Monday 15/09/2014 | 08:00-10:30

Paper Time: 08:24

Venue: Capital Hall B

First Author: : C.Lisa SPAIN

Co Author(s): :    B. Alfonso-Bartolozzi   L. Fernández-Vega Cueto   J. Alfonso        

Abstract Details

Purpose:

To assess the predictability, stability, safety and efficacy of the V4b toric and V4c toric Implantable Collamer lens (TICL) to correct moderate and high astigmatism.

Setting:

Instituto Oftalmológico Fernández-Vega. Oviedo. Spain.

Methods:

This study evaluated 35 eyes of 20 patients implanted with a TICL V4b and 32 eyes of 18 patients with a TICL V4c. In the V4b group, the mean sphere was -5.46 diopters (D) ± 4.17 (SD) (range -12 to +3 D) and the mean cylinder, -3.14 ± 1.19 D (range -6 to -1.50 D). In the V4c group, the mean sphere was -6.55 ± 2.96 D (range -12 to +3.25 D) and the mean cylinder was -2.99 ± 1.20 D (range -6 to -1.50 D). Uncorrected (UDVA) and corrected distance visual acuity (CDVA), refraction, TICL vault and adverse effects were evaluated over 6 months.

Results:

Refractive and visual outcomes with V4b and V4c TICLs are very similar. The mean sphere was -0.04 ± 0.16 D (range -0.75 to 0 D) with 97% of the eyes within ± 0.50 D of the target (r2=0.99) and -0.03 ± 0.09 D (range -0.25 to 0 D) with 85% of eyes within ± 0.50 D of the target (r2=0.99) for V4b and V4c. The mean cylinder was -0.29 ± 0.42 D (range -1 to 0 D) and -0.28 ± 0.54 D (range -1.50 to 0 D) with 65% and 73% of the eyes having less than 0.25 D of refractive cylinder, for V4b and V4c, respectively. The mean Snellen UDVA were 0.89 ± 0.16 and 0.94 ± 0.12; mean CDVA were 0.95 ± 0.12 and 0.99 ± 0.05 for V4b and V4c groups, respectively. For the V4b group, 77% had CDVA of 20/20, no eyes lost any line of CDVA and 43% of eyes gained 1 line or more. The safety index was 1.08 at 6 months. For V4c group, 93% had CDVA of 20/20, no eyes lost any line of CDVA and 60% of eyes gained 1 line or more. The safety index was 1.1 at 6 months.

Conclusions:

Visual and refractive outcomes were good, comparable and stable throughout the follow-up period with both TICL models evaluated; showing that these TICLs are predictable, stable, safe and effective to correct low and high levels of astigmatism. Furthermore, no intraoperative or postoperative complications were observed at 6 months follow-up with any TICL evaluated.

Financial Interest:

NONE

Back to previous